Slide 1: Corporate Responsibility & P|ESG Report 2025
Corporate Responsibility & P|ESG Report 2025 www.ascendispharma.com
Slide 2: Table of contents
Patients| Environmental, Social and Governance Report (P|ESG) Introduction Introduction 03 A message from our Executive Management Team 04 Who We Are 05 Mission & Vision 06 Innovation 07 A Brief History 08 Global Presence 09 Products, Programs & Pipeline P|ESG Approach P|ESG Approach 20 2025 Corpora
Slide 3: A message from our Executive Management Team
A message from our Executive Management Team At Ascendis Pharma, we remain dedicated to improving the lives of patients by applying our innovative TransCon® technology platform to Introduction develop new therapies demonstrating best-in-class potential to address unmet medical needs. Corporate respo
Slide 4: Who We Are
Who We Are Ascendis Pharma was founded in 2007. We are a global biopharmaceutical company focused on applying our innovative TransCon® technology platform to make a meaningful difference for patients and their families. Guided by our core values of Patients, Science and Passion, and following our al
Slide 5: Our Mission and Vision
Our Mission We are applying our innovative TransCon® technology platform to develop novel therapies demonstrating best-in-class potential to address unmet medical needs. Our Vision Introduction Our vision is to create new therapies focused on making a meaningful difference in patients’ lives. Vision
Slide 6: Innovation: TransCon central to our approach
Innovation TransCon®: Central to our innovative approach The TransCon® name derives from transient conjugation, our unique ability to temporarily (transiently) link an inert carrier to Introduction Parent Drug a parent drug with known biology to achieve sustained release. TransCon® technologies comb
Slide 7: A Brief History
A Brief History 2007 Ascendis Pharma is established. 2008 TransCon® hGH is created. 2009 Transition from pre-clinical to clinical company. Introduction 2014 TransCon® CNP is created. 2015 U.S. Nasdaq listing. 2018 TransCon® PTH is created. Vision 2020 established. P|ESG Approach Strategic investment
Slide 8: Global Presence
Global Presence Introduction P|ESG Approach Impact Ambitions Strategic investment and Direct markets Exclusive distribution agreement exclusive license agreement Exclusive license agreement 8
Slide 9: Products, Programs & Pipeline
Introduction P|ESG Approach Products, Programs Impact & Pipeline Ambitions We currently have two marketed products and a diversified portfolio of product candidates in clinical development. 9
Slide 10: Endocrinology Rare Disease
Endocrinology Rare Disease We built our first pipeline in Endocrinology Rare Diseases because it is an area where we saw the potential of TransCon® technology to address unmet medical needs. Each of our endocrinology product candidates has best-in-class potential, and each leverages established biol
Slide 11: Growth Hormone Deficiency
Growth Hormone Deficiency What is Growth Hormone Deficiency (GHD)? Growth hormone is essential in overall endocrine health, promoting growth and maintaining normal body composition, cardiovascular function, and metabolism. For children with GHD, their bodies do not make or release enough growth horm
Slide 12: Growth Hormone Deficiency 2025 Highlights
Growth Hormone Deficiency 2025 Highlights • Since its launch in 2021, Skytrofa® has been prescribed to more than 11,000 patients. • Received FDA approval of Skytrofa® for adult growth hormone deficiency, which represents the first of multiple planned label expansions. • Phase 3 trials with TransCon®
Slide 13: Hypoparathyroidism
Hypoparathyroidism What is Hypoparathyroidism? Hypoparathyroidism is a rare endocrine disease, caused by insufficient levels of parathyroid hormone (PTH) in the body.1 The parathyroid glands lie behind the thyroid gland in the neck. They produce PTH, which is the primary regulator of calcium and pho
Slide 14: Hypoparathyroidism 2025 Highlights
Hypoparathyroidism 2025 Highlights • 2025 was the first full year of the U.S. launch, with more than 5,300 patients being prescribed Yorvipath® by more than 2,400 unique prescribers. • Outside the U.S. and select EU countries, we have expanded our international sales footprint with distribution agre
Slide 15: Living with Hypoparathyroidism – Sabine's Story
Living with Hypoparathyroidism – Sabine’s Story Sabine has been living with hypoparathyroidism for 17 years. She is 66 years old. She describes her journey as a long and challenging path back to a self-determined life. Her story began in January 2008, when she underwent thyroid surgery because of mu
Slide 16: Living with Hypoparathyroidism – Sabine's Story
Living with Hypoparathyroidism – Sabine’s Story Sabine remained determined to regain control. She actively sought help from specialists, wrote letters and advocated for the care she needed. “I reached a point where I was desperate. I wrote to my endocrinologist: I have palpitations. I feel depressed
Slide 17: Achondroplasia
Achondroplasia What is Achondroplasia? Achondroplasia is a rare genetic condition arising from a systemic fibroblast growth factor receptor 3 (FGFR3) variant that leads to an imbalance in the effects of the FGFR3 and C-type natriuretic peptide signaling pathways, estimated to affect more than 250,00
Slide 18: Achondroplasia 2025 Highlights
Achondroplasia 2025 Highlights TransCon® CNP • Submitted new drug application (NDA) to the U.S. Food and Drug Administration (FDA). • Submitted marketing authorization application (MAA) to the European Medicines Agency (EMA). • Pivotal ApproaCH Trial demonstrated significant improvements in linear g
Slide 19: Pipeline
Pipeline Our pipeline of TransCon® therapies is driven by the flexibility of our innovative drug development platform and our aim to improve patients’ lives. Ascendis Pharma and its partners have multiple drug therapies in development. Each product candidate is unique and designed to be a best-in-cl
Slide 20: 2025 Corporate Responsibility & P|ESG Highlights
2025 Corporate Responsibility & P|ESG Highlights In 2025, we continued to advance our Corporate Responsibility and P|ESG efforts, focusing on strengthening existing processes and maintaining alignment with evolving regulatory and stakeholder expectations. Patients • Launched Yorvipath® in the U.S.,
Slide 21: Our Corporate Responsibility & P|ESG Approach
Our Corporate Responsibility & P|ESG Approach Our 2025 Corporate Responsibility & P|ESG Report is structured around our four key focus areas: Patients, Environmental, Social and Governance. Through these pillars, we aim to uphold our environmental and social license to operate while supporting long-
Slide 22: P|ESG Governance
P|ESG Governance Corporate Responsibility and P|ESG reporting at Ascendis Pharma is supported by a governance structure that promotes a collaborative and integrated approach across the organization. The Ethics & Compliance Committee, which includes members of Executive Management, continues to play
Slide 23: Key Topics
Key Topics As part of our ongoing commitment to P|ESG and reporting on the topics that matter most to our business and the patients we serve, we maintain our focus on the key areas identified as priorities for Ascendis Pharma and our stakeholders, considering both impact and relevance to our operati
Slide 24: P|ESG Risks
P|ESG Risks Given the nature of our business, we face a range of ESG risks. Proactively addressing these risks – especially those with the potential to influence our operations – supports continuity and helps safeguard the reputation of Ascendis Pharma. Risk Description Impact Mitigating Actions Pat
Slide 25: Patients
Patients Patient Focus Clinical Trials • Clinical Trial Safety, Data Integrity and Transparency • Clinical Trial Representation Product Safety Access & Affordability • Named Patient Programs • Access Support in the U.S. Patient & Caregiver Engagement • Patient Support Programs – EU Direct Markets •
Slide 26: Patients at the heart of all that we do
At Ascendis Pharma, patients are at the heart of all that we do. From the development of safe and effective medicines to their responsible commercialization, we strive to understand, support and advocate for the communities we serve. Listen No one knows the disease journey better than patients, fami
Slide 27: Clinical Trials
At the heart of our decision-making is a steadfast Ascendis Pharma aims to follow the principles We believe in clinical trial transparency as a commitment to addressing unmet medical needs of the Declaration of Helsinki and all relevant scientific, ethical and legal commitment and are and improving
Slide 28: Product Safety and Access & Affordability
Lastly, we recognize that the broader challenge corrective and preventive actions to maintain Named Patient Programs of finding trial sites that serve a representative high levels of product safety. To reinforce our For some countries there is a significant gap range of populations is a global issue
Slide 29: Patient & Caregiver Engagement
Patient & Caregiver Engagement reflects our belief that meaningful progress • Patient empowerment with knowledge and happens only when we work in true partnership. resources Over the past year, we strengthened our • Enhanced patient satisfaction commitment to improving the lives of individuals Our 2
Slide 30: Patient Registry
Patient Registry Patient registries allow us to learn from patients’ lived experiences beyond the clinical trial setting. By following patients over time, registries provide valuable insights into long-term safety, effectiveness and quality-of-life outcomes, helping to inform better care and support
Slide 31: 2025 and 2026 Patients Ambitions
2025 and 2026 Corporate Responsibility and P|ESG Ambitions 2025 Ambitions Status Description 2026 Ambitions Significant regulatory developments, including Review the material impacts, risks and the evolving CSRD and ESRS requirements, led In opportunities related to our patients as us to pause our D
Slide 32: Environmental
Environmental Climate Impact Suppliers & Business Partners Introduction P|ESG Approach Impact Ambitions 32
Slide 33: Environmental impact across the value chain
At Ascendis Pharma, we understand the importance of managing our environmental impact across the full value chain. Although we do not own manufacturing sites, we work closely with Contract Development and Manufacturing Organizations (CDMOs), logistics providers, research partners and other third-par
Slide 34: Climate Impact and Suppliers & Business Partners
effort supports our work toward disclosing applicable Scope 3 emissions in the future. Our climate initiatives continue to prioritize improved data robustness and strengthened alignment with regulatory requirements, reinforcing our long-term commitment to environmental responsibility. Suppliers & Bu
Slide 35: 2025 and 2026 Environmental Ambitions
2025 and 2026 Corporate Responsibility and P|ESG Ambitions 2025 Ambitions Status Description 2026 Ambitions Continue and further standardize Scope 1 and Scope Significant regulatory developments, 2 greenhouse gas emissions Review the material environmental including the evolving CSRD and ESRS report
Slide 36: Social
Social Employee Engagement & Development Inclusive Culture Health & Safety People in our Value Chain Human Rights Introduction P|ESG Approach Impact Ambitions 36
Slide 37: Social chapter introduction
In 2025, we recruited and onboarded more than 300 new employees worldwide, marking another year of significant growth at Ascendis Pharma. Today, more than 1,180 skilled and dedicated employees collaborate across functions and locations to advance our mission. Driven by science, we remain focused on
Slide 38: Employee Engagement and Inclusive Culture
initiative, we aim to create opportunities for personal development that ultimately contribute to the collective success of Ascendis Pharma. Employee feedback remains an important part of how we evolve our culture and practices, and we invite employees to share their perspectives through various sur
Slide 39: Health & Safety
stakeholders to help maintain a safe and compliant work environment. In our Headquarters, our local Danish Environment, Health & Safety organization (Arbejdsmiljøorganisation) oversees efforts to maintain and improve workplace safety. Comprised of a Health & Safety Committee and a Health & Safety Gr
Slide 40: People in our Value Chain
People in our Value Chain As outlined in the Environmental section, our business relies on a network of partners and suppliers who are responsible for manufacturing our products. We expect these partners and suppliers to uphold strong practices and standards of integrity, including compliance with a
Slide 41: 2025 and 2026 Social Ambitions
2025 and 2026 Corporate Responsibility and P|ESG Ambitions 2025 Ambitions Status Description 2026 Ambitions Ascendis Pharma continues to grow with a Attraction, onboarding and Attraction, onboarding and retention of talent continued focus to attract and retain the right retention of talent to ensure
Slide 42: Governance
Governance Business Conduct & Ethics • The Ascendis Pharma Business Ethics & Compliance Program • Effective and Tailored Compliance Training Anti-Corruption & -Bribery Responsible Marketing • Transparent Interactions • Promotional Review & Compliance Data Governance • Data Ethics • Data Privacy Cybe
Slide 43: Governance chapter introduction
At Ascendis Pharma, we remain dedicated to conducting our business responsibly, upholding high ethical standards and complying with applicable laws and regulations. Compliant behavior is fundamental to our Corporate Responsibility & P|ESG Reporting framework and central to how we operate as a biopha
Slide 44: Business Ethics & Compliance Program
The Ascendis Pharma Business Ethics & Compliance Program The Ascendis Pharma Compliance Program supports our efforts to maintain robust ethical standards and comply with applicable business conduct-related laws and regulations. It encompasses our Code of Business Conduct & Ethics, the development an
Slide 45: Compliance Training and Anti-Corruption & -Bribery
Effective and Tailored Compliance Training Anti-Corruption & -Bribery Policy All interactions with these stakeholders must have a legitimate purpose and fully comply with Training plays a critical role in maintaining a The Anti-Corruption & -Bribery Policy strictly the applicable regulations governi
Slide 46: Data Governance and Cybersecurity
others who administer, prescribe, purchase or Our focus continues to be on strengthening data risk management program designed to recommend regulated healthcare products, must ethics so that employees and partners clearly safeguard the confidentiality and integrity of the meet similar high standards
Slide 47: Speak Up Policy & Whistleblower Hotline
Whistleblower Hotline Policy • An external and internal Security Operations Speak Up Policy & Whistleblower Hotline Our Whistleblower Hotline provides a secure Center (SOC) performing advanced and trusted channel for raising concerns. We encourage and expect employees to raise Employees as well as e
Slide 48: Animal Welfare
Animal Welfare our high standards for the housing and care of experimental animals. To address animal welfare Animal studies are required by regulatory at suppliers of animal-derived biological matrices authorities and play an important role in the for Ascendis Pharma studies, an audit program devel
Slide 49: 2025 and 2026 Governance Ambitions
2025 and 2026 Corporate Responsibility and P|ESG Ambitions 2025 Ambitions Status Description 2026 Ambitions Continuous work with the establishment as well Further strengthen our Global Compliance Continue building and Ongoing as updating of global compliance framework Framework. strengthening our Co
Slide 50: 2026 Corporate Responsibility & P|ESG Ambitions
2026 Corporate Responsibility & P|ESG Ambitions In 2026, we will continue strengthening our Corporate Responsibility and P|ESG framework by ensuring strong alignment with the Ascendis Pharma strategy and evolving regulatory requirements, and by advancing the processes that support consistent, accura
Slide 51: Forward-looking statements
This report may contain forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition, including with relation to our corporate responsibili
Slide 52: Ascendis Pharma A/S contact details
Ascendis® Ascendis Pharma A/S (Company Reg. No. 29918791) Tuborg Boulevard 12 2900 Hellerup Denmark Tel: +45 70 22 22 44 Ascendis, Ascendis Pharma, Ascendis Pharma logo, the company logo, Skytrofa, Yorvipath, Ascendis Signature Access Program and TransCon are trademarks owned by the Ascendis Pharma